M
Mark J. O'Connor
Researcher at AstraZeneca
Publications - 164
Citations - 17011
Mark J. O'Connor is an academic researcher from AstraZeneca. The author has contributed to research in topics: Olaparib & PARP inhibitor. The author has an hindex of 55, co-authored 150 publications receiving 14035 citations. Previous affiliations of Mark J. O'Connor include University of Edinburgh & Medical University of South Carolina.
Papers
More filters
Journal ArticleDOI
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Peter C.C. Fong,D. S. Boss,Timothy A. Yap,Andrew Tutt,Peijun Wu,Marja Mergui-Roelvink,Peter S. Mortimer,Helen Swaisland,Alan Lau,Mark J. O'Connor,Alan Ashworth,James Carmichael,Stan B. Kaye,Jan H.M. Schellens,Jan H.M. Schellens,Johann S. de Bono +15 more
TL;DR: Olaparib has few of the adverse effects of conventional chemotherapy, inhibits PARP, and has antitumor activity in cancer associated with the BRCA1 or BRCa2 mutation.
Journal ArticleDOI
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.
Nuala McCabe,Nicholas C. Turner,Christopher J. Lord,Katarzyna Kluzek,Aneta Białkowska,Sally Swift,Sabrina Giavara,Mark J. O'Connor,Andrew Tutt,Małgorzata Z. Zdzienicka,Graeme C. M. Smith,Alan Ashworth +11 more
TL;DR: The results indicate that PARP inhibition might be a useful therapeutic strategy not only for the treatment of BRCA mutation-associated tumors but also for a wider range of tumors bearing a variety of deficiencies in the HR pathway or displaying properties of 'BRCAness.
Journal ArticleDOI
Targeting the DNA Damage Response in Cancer
TL;DR: The recent approval of olaparib (Lynparza) represents the first medicine based on this principle, exploiting an underlying cause of tumor formation that also represents an Achilles' heel.
Journal ArticleDOI
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Sven Rottenberg,Janneke E. Jaspers,Ariena Kersbergen,Eline van der Burg,Anders O.H. Nygren,Serge A.L. Zander,Patrick W. B. Derksen,Michiel de Bruin,John Zevenhoven,Alan Lau,Robert Boulter,Aaron Cranston,Mark J. O'Connor,Niall M. B. Martin,Piet Borst,Jos Jonkers +15 more
TL;DR: In vivo efficacy of AZD2281 against BRCA1-deficient breast cancer is demonstrated and how GEMMs of cancer can be used for preclinical evaluation of novel therapeutics and for testing ways to overcome or circumvent therapy resistance is illustrated.
Journal ArticleDOI
4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.
Keith Allan Menear,Claire Adcock,Robert Boulter,Xiao-Ling Fan Cockcroft,Louise Copsey,Aaron Cranston,Krystyna J. Dillon,Jan Drzewiecki,Sheila Garman,Sylvie Gomez,Hashim Javaid,Frank Kerrigan,Charlotte Knights,Alan Lau,Vincent Junior Ming-Lai Loh,Ian Timothy William Matthews,Stephen Moore,Mark J. O'Connor,Graeme C. M. Smith,Niall M. B. Martin +19 more
TL;DR: A novel series of substituted 4-benzyl-2 H-phthalazin-1-ones that possess high inhibitory enzyme and cellular potency for both PARP-1 andPARP-2 are disclosed and shows standalone activity against BRCA1-deficient breast cancer cell lines.